Imagen de Portada

CHD6 drives an immunosuppressive vascular ecotype and therapy resistance in hepatocellular carcinoma

Fuente: Zenodo

Guardado en:

Detalles Bibliográficos
Autores principales:	Fan, Xutong, Zhang, Min
Formato:	Recurso digital
Publicado:	Zenodo 2026
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Tumor-associated CD19$^+$ macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma
por: Wang, Junli, et al.
Publicado: (2025)

Emerging nanomedicine strategies for hepatocellular carcinoma therapy
por: Chen Guo, et al.
Publicado: (2024)

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives
por: Jian‐Jian Chen, et al.
Publicado: (2024)

Systemic therapies in hepatocellular carcinoma: A revolution?
por: Marta Fortuny, et al.
Publicado: (2024)

Exosomal miR‐93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway
por: Yuanpeng Bao, et al.
Publicado: (2024)

Effectiveness of add‐on acetazolamide in children with drug‐resistant CHD2‐related epilepsy and in a zebrafish CHD2 model
por: Gia Melikishvili, et al.
Publicado: (2024)

Mitochondrial metabolism: A moving target in hepatocellular carcinoma therapy
por: Monika Komza, et al.
Publicado: (2024)

PPM1G‒MET axis sustains AKT signaling to drive Twist‐associated EMT and drug resistance in hepatocellular carcinoma
por: Weixun Wu, et al.
Publicado: (2026)

Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy
por: Shinsei Yumoto, et al.
Publicado: (2024)

Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
por: Dai Lian, et al.
Publicado: (2024)

MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance of hepatocellular carcinoma
por: Soe Thiha Maung, et al.
Publicado: (2024)

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma
por: Jiayin Lin, et al.
Publicado: (2026)

Methylation in hepatocellular carcinoma
por: REGINA M. SANTELLA
Publicado: (2007)

Epidemiology of hepatocellular carcinoma
por: RAYMUNDO PARANÁ
Publicado: (2007)

Natural products targeting macroautophagy signaling in hepatocellular carcinoma therapy: Recent evidence and perspectives
por: Yuan Chen, et al.
Publicado: (2024)

Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma
por: Mosunmoluwa Oyenuga, et al.
Publicado: (2025)

Recent advances in systemic therapies for unresectable hepatocellular carcinoma and their impact on clinical outcomes
por: Kyoko Oura
Publicado: (2025)

USP22 promotes the proliferation and Sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity
por: Xiaochen Wang, et al.
Publicado: (2025)

NS3 of hepatitis C virus drives hepatocellular carcinoma progression through a novel RNA‐interference pathway
por: Yajun Liang, et al.
Publicado: (2025)

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study
por: Jun‐Zhe Yi, et al.
Publicado: (2024)

Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma
por: Hironori Ochi, et al.
Publicado: (2025)

A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2025)

Whole‐exome sequencing‐based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma
por: Yichao Bu, et al.
Publicado: (2024)

TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling
por: Fatma El Zahraa Ammar Mohamed, et al.
Publicado: (2024)

Perfusion of hepatocellular carcinomas measured by diffusion‐derived vessel density biomarker: Higher hepatocellular carcinoma perfusion than earlier intravoxel incoherent motion reports
por: Xin‐Ming Li, et al.
Publicado: (2024)

CircETV6 acts as an oncogenic driver in hepatocellular carcinoma progression
por: Xiaoqin Li, et al.
Publicado: (2024)

Delta virus infection and hepatocellular carcinoma
por: Maurizio Bonacini
Publicado: (2024)

Intrahepatic splenosis mimicking hepatocellular carcinoma
por: Martina Rosi, et al.
Publicado: (2024)

Clinical and laboratory features of hepatocellular carcinoma
por: MARIA C. LONDOÑO
Publicado: (2007)

Immunosupression in liver transplant for hepatocellular carcinoma
por: JUAN-CARLOS RESTREPO
Publicado: (2007)

Hepatitis infections, aflatoxin and hepatocellular carcinoma
por: PIERRE HAINAUT
Publicado: (2007)

The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma
por: Shuwen Kuang, et al.
Publicado: (2024)

Metabolic‐associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy
por: NM Batt, et al.
Publicado: (2024)

Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy
por: Sha She, et al.
Publicado: (2024)

FactCHD: Benchmarking Fact-Conflicting Hallucination Detection
por: Chen, Xiang, et al.
Publicado: (2023)

Targeting the NSUN5-circPPAP2A axis reverses immunosuppression and sensitizes renal cell carcinoma to anti-PD-1 therapy
por: First Affiliated Hospital of Guangzhou Medical University
Publicado: (2026)

Genotype-phenotype modeling of light ecotypes in reveals genomic signatures of ecotypic divergence.
por: Brenner, Evan, et al.
Publicado: (2026)

Sister Mary Joseph's nodule in hepatocellular carcinoma
por: Arpit Shastri, et al.
Publicado: (2024)

Opportunities to improve surveillance of hepatocellular carcinoma in Australia
por: Jess Howell, et al.
Publicado: (2025)

Proteomics for the early diagnosis and treatment of hepatocellular carcinoma
por: VIJAY KUMAR
Publicado: (2007)